Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sierra Oncology Inc (SRRA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Sierra Oncology Reports Preclinical Efficacy for Chk1 inhibitor SRA737 in Treatment Refractory Ovarian Cancer Models at the EORTC-NCI-AACR Symposium

SRA737 demonstrates preclinical efficacy in aggressive CCNE1-amplified and MYCN--overexpressing high-grade serous ovarian cancer patient-derived xenograft (PDX) models -- PDX models were refractory to...

SRRA : 1.71 (+3.01%)
Sierra Oncology Reports SRA141 Preclinical Efficacy at EORTC-NCI-AACR Symposium

Novel oral Cdc7 inhibitor, SRA141, demonstrates competitive target selectivity and robust efficacy in several cancer models -

SRRA : 1.71 (+3.01%)
Sierra Oncology Reports Third Quarter Results

Momelotinib regulatory pathway clarity anticipated in H1 2019 - - SRA737 Monotherapy and LDG Combination trial preliminary data anticipated in H1 2019 -

SRRA : 1.71 (+3.01%)
Sierra Oncology to Present at the Jefferies 2018 London Healthcare Conference

- "Targeted Therapeutics for Hematology & Oncology" scheduled for 5:20 p.m. GMT on November 14, 2018 -

SRRA : 1.71 (+3.01%)
Sierra Oncology to Report Clinical Data at ASH 2018 from Translational Biology Study of Momelotinib in Transfusion Dependent Patients

Biomarker data obtained from 41 transfusion dependent patients support ACVR1 mechanism of action for momelotinib's anemia benefit in myelofibrosis -

SRRA : 1.71 (+3.01%)
Sierra Oncology to Host KOL Call with Dr. Srdan Verstovsek Presenting "Unmet Medical Needs in Myelofibrosis"

Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and oncology,...

SRRA : 1.71 (+3.01%)
Sierra Oncology (SRRA): Moving Average Crossover Alert

Sierra Oncology, Inc. (SRRA) could be a stock to avoid from a technical perspective

SRRA : 1.71 (+3.01%)
Sierra Oncology Acquires Momelotinib, an Investigational Janus Kinase (JAK) 1/2 and Activin Receptor Type 1 (ACVR1) Inhibitor for Myelofibrosis, from Gilead Sciences

More than 1,200 patients treated to date with momelotinib, including in two Phase 3 trials; ongoing therapy for more than seven years in some patients -

SRRA : 1.71 (+3.01%)
GILD : 69.20 (-0.83%)
Sierra Oncology Reports Second Quarter Results

SRA737 Monotherapy trial prioritized for ovarian cancer; targeting enrollment of 65 patients with preliminary data anticipated in H1 2019 - - SRA737 LDG Combination trial to be amended and prioritized...

SRRA : 1.71 (+3.01%)
Sierra Oncology Reports First Quarter Results

SRA737 Monotherapy Phase 1/2 trial expanded to enroll CCNE1-driven ovarian cancer cohort - - SRA737 Low-Dose Gemcitabine Combination Phase 1/2 trial advanced into cohort expansion phase - - $133.8 million...

SRRA : 1.71 (+3.01%)
Sierra Late-Breaking Data Demonstrating SRA737 Preclinical Activity with PARPi to be Presented at the AACR 2018 Annual Meeting

Sierra Late-Breaking Data Demonstrating SRA737 Preclinical Activity with PARPi to be Presented at the AACR 2018 Annual Meeting

SRRA : 1.71 (+3.01%)
Sierra Oncology to Present at the Future Leaders in the Biotech Industry Conference in New York

Sierra Oncology to Present at the Future Leaders in the Biotech Industry Conference in New York

SRRA : 1.71 (+3.01%)
Pre-Market Technical Scan on Biotech Equities -- Riot Blockchain, Sage Therapeutics, Sarepta Therapeutics, and Sierra Oncology

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on RIOT, SAGE, SRPT, and SRRA which can be accessed for free by signing up to www.wallstequities.com/registration....

SRPT : 119.04 (+0.07%)
SRRA : 1.71 (+3.01%)
RIOT : 2.19 (-2.45%)
SAGE : 114.21 (+2.08%)
Late-Breaking Abstract Reporting SRA737 Preclinical Activity in CCNE1-Driven and PARPi-Resistant Cancers Accepted for AACR 2018 Annual Meeting

Late-Breaking Abstract Reporting SRA737 Preclinical Activity in CCNE1-Driven and PARPi-Resistant Cancers Accepted for AACR 2018 Annual Meeting

SRRA : 1.71 (+3.01%)
Sierra Oncology Announces Pricing of Public Offering of Common Stock

Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response therapeutics for the treatment of patients with cancer, today announced...

SRRA : 1.71 (+3.01%)
Sierra Oncology Announces Proposed Public Offering of Common Stock

Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response therapeutics for the treatment of patients with cancer, today announced...

SRRA : 1.71 (+3.01%)
Sierra Oncology Significantly Expands Clinical Development Program

Ongoing SRA737 clinical studies expanded to target aggregate enrollment of 200 patients across ten cancer indications -- Adding new SRA737 monotherapy cohort for CCNE1-driven ovarian cancer -- SRA141 IND...

SRRA : 1.71 (+3.01%)
Sierra Oncology and Janssen Sign Supply Agreement for Prostate Cancer Study

Janssen to supply PARP inhibitor niraparib for Sierra's Phase 1b/2 combination trial with Chk1 inhibitor SRA737 -

SRRA : 1.71 (+3.01%)

Van Meerten Stock Picks

Tesla According to Peter Lynch
Today's Barchart Chart of the Day will be the auto maker Tesla (TSLA).
TSLA +5.87
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

cmdty Insider - Ag Market Commentary

Today's Commentary

Corn futures ended the Friday session with most contracts steady to 2 3/4 cents lower heading into the pre-Thanksgiving weekend. Nearby Dec was down a nickel on the week. Ethanol was slightly lower on the day. This morning’s Export Sales report...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar